M L Hetland1, D V Jensen, N S Krogh. 1. DANBIO, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Glostrup, Denmark. merete.hetland@dadlnet.dk.
Abstract
OBJECTIVES: Advances in aggressive use of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) as well as biological DMARDs (bDMARDs) have improved the treatment armamentarium for rheumatologists, and modern treatment principles include a treat-to-target (T2T) strategy. However, little is known about the feasibility of a T2T strategy in patients with rheumatoid arthritis (RA) treated in routine care. The aim of the present study was to (i) present the annual number of patients included in DANBIO between 2006 and 2013 and their disease characteristics and (ii) estimate coverage of DANBIO by 2013. METHODS: Patients who were registered with RA for the first time in the nationwide Danish DANBIO database between year 2006 and 2013 were included. Baseline characteristics were assessed in patients treated with bDMARDs and csDMARDs, respectively. The fraction of patients with low/moderate/high disease activity (i.e. DAS28 (CRP-based, 4 variables) was calculated for each calendar year. RESULTS: From 2006-2013 the number of patients increased from 2,395 to 14,249. By 2013, 29.8% of patients were receiving bDMARD. Patients in the csDMARD group were older, had shorter disease duration, lower disease activity, less disability and radiographic damage. By 2013, 19% of csDMARD (15% of bDMARD) patients were in ACR/Boolean remission. Coverage had increased to between 41% and 79% for patients with RA, for the bDMARD group it was 94%. CONCLUSIONS: Systematic monitoring of RA patients with real-time feedback to the physician is feasible, although the goal of treat-to-target is not achieved in a substantial proportion of patients in routine care.
OBJECTIVES: Advances in aggressive use of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) as well as biological DMARDs (bDMARDs) have improved the treatment armamentarium for rheumatologists, and modern treatment principles include a treat-to-target (T2T) strategy. However, little is known about the feasibility of a T2T strategy in patients with rheumatoid arthritis (RA) treated in routine care. The aim of the present study was to (i) present the annual number of patients included in DANBIO between 2006 and 2013 and their disease characteristics and (ii) estimate coverage of DANBIO by 2013. METHODS:Patients who were registered with RA for the first time in the nationwide Danish DANBIO database between year 2006 and 2013 were included. Baseline characteristics were assessed in patients treated with bDMARDs and csDMARDs, respectively. The fraction of patients with low/moderate/high disease activity (i.e. DAS28 (CRP-based, 4 variables) was calculated for each calendar year. RESULTS: From 2006-2013 the number of patients increased from 2,395 to 14,249. By 2013, 29.8% of patients were receiving bDMARD. Patients in the csDMARD group were older, had shorter disease duration, lower disease activity, less disability and radiographic damage. By 2013, 19% of csDMARD (15% of bDMARD) patients were in ACR/Boolean remission. Coverage had increased to between 41% and 79% for patients with RA, for the bDMARD group it was 94%. CONCLUSIONS: Systematic monitoring of RApatients with real-time feedback to the physician is feasible, although the goal of treat-to-target is not achieved in a substantial proportion of patients in routine care.
Authors: Bee Eng Tan; Ai Lee Lim; Sow Lai Kan; Chong Hong Lim; Ying Fun Ng; Serene Li Ching Tng; Nur Syakirah Hassin; Losshenee Chandran; Norshahida Abdul Hamid; Yvonne Yin Leng Lee Journal: Rheumatol Int Date: 2017-04-07 Impact factor: 2.631
Authors: Else Helene Ibfelt; Jan Sørensen; Dorte V Jensen; Lene Dreyer; Berit Schiøttz-Christensen; Pia H Thygesen; Ada Colic; Johnny L Raun; Natalia Manilo; Anne Rødgaard; Uta E Poulsen; Claus Rasmussen; Torben Hansen; Babara Unger; Randi Pelck; Anita Kincses; Henrik Nordin; Tove Lorenzen; Ali Theibich; Inger Marie Jensen Hansen; Jakob Espesen; Jolanta Grydehøj; Mette Holland-Fischer; Anne Gitte Loft; Merete Lund Hetland Journal: Clin Epidemiol Date: 2017-11-29 Impact factor: 4.790
Authors: S Rifbjerg-Madsen; A W Christensen; R Christensen; M L Hetland; H Bliddal; L E Kristensen; B Danneskiold-Samsøe; K Amris Journal: PLoS One Date: 2017-07-07 Impact factor: 3.240
Authors: Peter C Taylor; Rieke Alten; Juan J Gomez Reino; Roberto Caporali; Philippe Bertin; Emma Sullivan; Robert Wood; James Piercy; Radu Vasilescu; Dean Spurden; Jose Alvir; Miriam Tarallo Journal: Patient Prefer Adherence Date: 2018-10-04 Impact factor: 2.711
Authors: Tina Marie Kringelbach; Bente Glintborg; Estrid V Hogdall; Julia Sidenius Johansen; Merete Lund Hetland Journal: BMJ Open Date: 2018-02-01 Impact factor: 2.692